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ABSTRACT
To improve the results in the treatment of adult acute lymphoblastic leukemia patients, different strategies
have been proposed. The intensification could concern the induction and early consolidation phases, the
conditioning regimen before allogeneic bone marrow transplantation (alloBMT), or both. We analyzed 2
consecutive trials for adult patients in first remission and with the same prognostic features. The Leucémie
Aiguë Lymphoblastique Paris-Ouest-France (LALPOF) protocol proposed alloBMT with standard condition-
ing after a classic induction and intensified consolidation scheme; the Groupe Ouest Est des Leucemies Aiguës
Lymphoblastiques (GOLEAL1) protocol tested an intensified induction and consolidation course before
alloBMT with a reinforced conditioning regimen. The 4-year survival rates after alloBMT for LALPOF and
GOELAL1 were, respectively, 71%  12% and 36%  13% (P  .009). The 4-year disease-free survival
reached 75%  11% in the LALPOF study and 69%  13% in the GOELAL1 study (P  .30). The toxic death
rate was significantly lower in the LALPOF (2/18) than in the GOELAL1 (6/15) group. Event-free survival at
4 years was significantly higher in LALPOF than in GOELAL1: 66%  11% and 35%  11%, respectively (P
 .02). For adult acute lymphoblastic leukemia patients in first remission, the intensification of chemotherapy
before a reinforced conditioning regimen before alloBMT may lead to an increased toxic death rate.
© 2005 American Society for Blood and Marrow Transplantation
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Intensified Allogeneic BMT in ALL
BNTRODUCTION
As demonstrated for several years in young pa-
ients, acute lymphoblastic leukemias (ALLs) are che-
osensitive diseases [1-3]. The intensiﬁcation of che-
otherapy in adults is limited by hematopoietic and
onhematopoietic toxicities [4-9]. Allogeneic hemato-
oietic stem cell transplantation (HSCT) remains for
ost clinicians the treatment of choice in adult ALL
atients in ﬁrst remission with an available HLA-
dentical donor [10-13]. Several protocols have tried
o combine the dose intensity and the graft-versus-
eukemia effect of HSCT in the treatment of ALL
14-17]. The achievement of a complete remission
CR) before transplantation is a crucial issue in the
ong-term outcome after HSCT. The nature of the
retransplantation chemotherapy could inﬂuence the
uality of this CR but also the occurrence of posttrans-
lantation toxicities [10,11,13,14,16-18]. During the
990s, the Groupe Ouest-Est d’Etude des Leucémies et
utres Maladies du Sang (GOELAMS) conducted 2
onsecutive prospective trials with different primary ob-
ectives. The ﬁrst one, named Leucémie Aiguë Lympho-
lastique Paris-Ouest-France (LALPOF) [18], tested the
ffect of continuous infusion of anthracyclines during
he induction phase, and the second, named Groupe
uest Est des Leucémies Aiguës Lymphoblastiques
GOELAL1) [4], studied the role of an intensive short-
erm induction therapy similar to the strategies used for
cute myeloblastic leukemia. In the LALPOF protocol,
atients received an induction scheme with a standard
ose intensity and a classic conditioning regimen be-
ore allogeneic bone marrow transplantation (al-
oBMT) [18]. In the GOELAL1 protocol, patients
eceived intensive induction and early consolidation
hemotherapies before alloBMT with a reinforced
reparative regimen. Both alloBMT arms were com-
arable in terms of recruitment but exhibited different
esults in terms of survival. We decided to reanalyze
oth databases by focusing on the patients who had
ndergone alloBMT to test whether it is better to
ntensify the consolidation courses, including the
lloBMT procedure. The results acted as a guide to
esigning the following protocol, named GOELAL02,
hich was recently published [12].
ETHODS
tudy Design
Data were extracted from 2 consecutive prospec-
ive randomized trials that included previously un-
reated ALL patients with comparable features: the
ALPOF [18] and GOELAL1 [4] studies. The trials
ere approved by the regional ethical committee, and
ll patients signed a written informed consent. In the
articipating GOELAMS centers, all investigators
ollowed the recommendations for good clinical prac- m
B & M Tice, and supportive care was performed according to
ach center policy; no signiﬁcant variations were ob-
erved in the patients’ management during both con-
ecutive trials. The cytologic diagnosis was based on
ay-Grunwald-Giemsa and cytochemical staining of
lood and marrow smears. The diagnosis of ALL was
ased on the French-American-British criteria [19]
nd completed by immunologic phenotyping with a
anel of monoclonal antibodies directed against B, T,
r myeloid antigens [20]. Banded chromosomes stud-
es were obtained from marrows at diagnosis in most
ases and were classiﬁed according to the Interna-
ional System for Human Cytogenetic Nomenclature
21,22]. Responses to therapy were assessed according
o the Cancer and Leukemia Group B criteria [9].
reatments
The principles used to deﬁne alloBMT eligibility
ere identical in both studies; patients in CR after 1 or
induction courses were scheduled for alloBMT only
f an HLA-identical sibling willing to act as a donor
as available, and no mismatched or unrelated allo-
MTs were performed. In the LALPOF protocol,
lloBMT took place after a standard consolidation
ycle and was conditioned with a standard total body
rradiation (TBI)-cyclophosphamide (CY) regimen. In
he GOELAL1 protocol, alloBMT was performed
ith an intensiﬁed conditioning regimen after a rein-
orced consolidation cycle.
The LALPOF protocol tested bolus versus con-
inuous infusion of daunorubicin during the induction
ourses, and the GOELAL1 protocol compared re-
ombinant human granulocyte-macrophage colony-
timulating factor versus placebo administration after
nduction chemotherapy [4,18] (Figure 1). Brieﬂy, in
he LALPOF protocol, patients received an induction
reatment with daunorubicin (60 mg/m2/d on days
-4) administered with vincristine (2 mg intravenously
IV] on days 1, 8, and 15) and oral prednisone (60
g/m2/d on days 1-15). Bone marrow evaluation was
erformed on day 21; patients not in CR received a
econd induction course named ADA (daunorubicin
0 mg/m2 on day 22, cytarabine 30 mg/m2 IV twice a
ay on days 24-28, and asparaginase 1000 IU/kg/d on
ays 30-42). All patients in CR after 1 or 2 induction
ycles with an age 45 years and an HLA-identical
ibling were eligible for an alloBMT after an addi-
ional ADA course; the conditioning regimen was a
tandard TBI-CY association. In the GOELAL1 pro-
ocol, induction therapy consisted of idarubicin 8 mg/
2/d on days 1 to 5, cytarabine 1 g/m2 every 12 hours
n days 1 to 3, and IV methylprednisolone 1 mg/kg/d
n days 1 to 6. A marrow aspiration was performed on
ay 21. Patients with persistent blasts received a sec-
nd induction course that comprised idarubicin 12
g/m2/d on day 22, cytarabine 30 mg/m2 IV twice a
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4ay on days 24 to 28, and asparaginase 1000 IU/kg/d
n days 30 to 42. All patients in CR after 1 or 2
nduction cycles aged 50 years with an HLA-iden-
ical donor were scheduled for an alloBMT after a
AME consolidation course (IV methylprednisolone
.5 mg/kg/d on days 1-5, cytarabine 1 g/m2 every 12
ours on days 1 to 4, mitoxantrone 12 mg/m2/d on
ays 1-3, and etoposide 200 mg/m2/d on days 6-8).
he conditioning regimens were intensiﬁed according
o local references in each center. The alloBMT pro-
edures were the same in both protocols. The marrow
rafts were not manipulated, and no growth factor was
dministered after bone marrow transplantation
BMT). The graft-versus-host disease (GVHD) pro-
hylaxis was standardized in all centers and comprised
yclosporine and 3 to 4 IV doses of methotrexate on
ays 1, 3, 6, and 11 after BMT; in the absence of
VHD, cyclosporine was progressively tapered from
he third until the sixth month after alloBMT. Sys-
ematic anti-infectious prophylaxis consisted of oral
cyclovir, ﬂuconazole, and phenoxymethylpenicillin
r spiramycin during the ﬁrst 6 months after al-
oBMT.
tatistical Analysis
The comparisons of patient characteristics were
igure 1. Protocol design of the LALPOF and GOELAL1 tri
aunorubicin; VCR, vincristine; ADA, daunorubicin  cytarabin
incristine; BEAC, BCNU (carmustine) etoposide cytarabine
ZA, cytarabine  idarubicin  asparaginase; PAME, prednisolonerformed by using the 2 test for discrete variables p
50nd the Student t test (or Wilcoxon rank-sum test in
onparametric situations) for continuous measures.
esponse rates were assessed with the 2 test except in
ase of small numbers, in which the Fisher exact test
as used. Survival curves were calculated by using the
aplan-Meier method [23]. Dates were recalculated
rom the original data sets of both protocols. Times
tarted from the day of marrow reinfusion until the
ay of death of any cause for survival, until disease
elapse or death due to any cause for event-free sur-
ival (EFS), and until disease relapse for disease-free
urvival (DFS). Differences in survival curves were
nalyzed by using the log-rank test. The differences
ere regarded as signiﬁcant if the 2-sided P value was
.05 [24].
ESULTS
atient Characteristics and
ransplantation Procedure
Between May 1, 1986, and April 30, 1992, 144 con-
ecutive patients with de novo non-Burkitt ALL and ages
anging from 15 to 65 years were randomized. Until
ay 1990, 77 patients were randomized in the LALPOF
rotocol, and 67 were randomized in the GOELAL1
indicates continuous infusion; CR, complete remission; DNR,
paraginase; MAPO, methotrexate  cytarabine  prednisone 
hosphamide; ZAM, idarubicin cytarabinemethylprednisolone;
tarabine  mitoxantrone  etoposide.als. CI
e  as
cycloprotocol after this date. In the LALPOF protocol, the
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Intensified Allogeneic BMT in ALL
BR rate was 72% after the induction phase, and
mong the 66 patients alive in CR, only 53 entered the
ate consolidation phase, because of early relapse or
oxic deaths. Thirty-ﬁve received autologous BMT,
ith 4-year EFS and survival reaching 18% and 26%,
espectively [18]; 18 (86%) of 21 eligible patients ac-
ually received an alloBMT according to the LALPOF
rotocol. In the GOELAL1 protocol, the CR rate was
1% after the induction phase. Among the 50 patients
live in CR, because of early relapse or toxic deaths,
nly 45 entered the ﬁrst consolidation phase, and 36
ntered the late consolidation phase; 18 received au-
ologous BMT, with 4-year EFS and survival reaching
8% and 21%, respectively [4]. Fifteen (83%) of the
8 eligible patients actually received an alloBMT ac-
ording to the GOELAL1 protocol.
The characteristics of the patients showed some
iscrepancies between protocols, but no difference
as signiﬁcant except a trend for a younger age in the
ALPOF group (Table 1). The alloBMT started at a
edian time of 12 weeks after the achievement of CR
n both groups (2-37 weeks in the LALPOF protocol
nd 3-35 weeks in the GOELAL1 protocol; P  .65).
n the LALPOF group, the conditioning regimens
omprised TBI (12 Gy in 6 fractions) and CY (120
g/kg in 2 days); only 2 patients (11%) received
dditional doses of cytarabine during their condition-
ng regimen. In the GOELAL1 group, 5 patients were
onditioned with a standard regimen: TBI plus CY in
cases and busulfan (4 mg/kg/d on 4 days) plus CY
50 mg/kg/d on 4 days) in 1 case. Preparative regimens
ere signiﬁcantly reinforced in 10 patients (67%; P 
001): TBI, CY, and etoposide (40 mg/kg on 1 day) in
cases and TAM 12 (TBI plus cytarabine 3 g/m2/12 h on
days plus melphalan 140 mg/m2 on 1 day) in 8 cases.
even patients received day 11 methotrexate for
VHD prophylaxis (5 in the LALPOF group and 2 in
able 1. Patient Characteristics
Variable LALPOF (n 
nclusion period (month/year) 5/1986 to 5/19
ex (M/F) 14/4
edian age 20 (17-40)
ge >30 y (n) 4
BC 109/L 17 (1.0-145.0
henotype
T 6
B 10
Biphenotypic 1
Not done 1
ytogenetics
Normal 2
Abnormal (excluding Ph1) 7
Ph1 2
Not done or failure 7
BC indicates white blood cell; Ph1, Philadelphia chromosome.he GOELAL1 group). G
B & M Turvival
The median follow-up for surviving patients
eached 121 months (range, 114-157 months) in the
ALPOF study and 47 months (range, 39-51 months)
n the GOELAL1 study. Despite a longer follow-up in
he LALPOF group, 13 (72%) of 18 grafted patients
ere alive, whereas only 6 (40%) of 15 patients in the
OELAL1 group survived. Three deaths were ob-
erved after a relapse of ALL in both groups. The
-year survival rates for the LALPOF and GOELAL1
roups were, respectively, 71%  12% and 36% 
3% (P  .009; Figure 2). By deﬁnition, all patients
ere in CR before transplantation, and the 4-year
GOELAL1 (n  15) P Value
11/1990 to 4/1992
10/5 .79
29 (19-46) .055
7
29 (1.3-107.0) .09
.1
3
8
2
2
.2
2
4
4
5
igure 2. Survival according to the protocol assignment. At 48
onths (4 years): LALPOF, 71%  12% (continuous line);18)
90
)OELAL, 36%  13% (dotted line) (P  .009).
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4FS reached 75%  11% in the LALPOF study and
9%  13% in the GOELAL1 study (P  .30; Figure
). In terms of EFS, at 4 years the difference between
ALPOF and GOELAL1 was signiﬁcant: 66% 
1% and 35%  11%, respectively (P  .02; Figure
). The median age was 29  9 years (range, 19-45
ears) in surviving patients of the GOELAL1 study
nd 26  7 years (range, 20-37 years) in the LALPOF
atients (P  .10). Posttransplantation survival was
ot affected by age, leukocytosis, or phenotypic or
ytogenetic features at diagnosis.
oxicity
The toxic death rate differed signiﬁcantly between
roups: 2 (11%) of 18 for the LALPOF patients (1
neumocystis infection on day 70 and 1 case of acute
VHD on day 76) and 6 (40%) of 15 for the
OELAL1 patients. Six toxic deaths occurred after a
einforced conditioning regimen (2 cases of interstitial
neumonitis on days 30 and 92 after TBI, CY, and
toposide; 2 leukoencephalopathies on days 50 and 90
fter TAM 12 conditioning; and 2 gram-negative septi-
emias on days 7 and 30, 1 after a TAM 12 regimen; P
.01). Severe (grade 3-4) mucositis was more frequent:
(53%) of 15 in the GOELAL1 patients versus 6 (33%)
f 18 in the LALPOF patients (P  .045). Other
onfatal complications were observed, but there was
o signiﬁcant difference between LALPOF and
OELAL1: 0 versus 2 cases of interstitial pneumoni-
is, 0 cases versus 1 case of veno-occlusive disease, 4
igure 3. Disease-free survival according to the protocol assign-
ent. At 48 months (4 years): LALPOF, 75%  11% (continuous
ine); GOELAL, 69%  13% (dotted line) (P  .30).ersus 6 grade II to IV cases of acute GVHD, and 2 G
52ersus 2 cases of extensive chronic GVHD, respec-
ively, in each group.
ISCUSSION
ALLs account for 15% to 20% of adult acute
eukemias [1-3,12]. They are heterogeneous disorders,
nd their response to therapy can vary dramatically
ccording to different prognostic features at diagnosis.
ore than 70% of children achieve long-term DFS,
hereas only 20% to 38% of adults do so [1-3]. These
esults, obtained with conventional chemotherapy,
ave led many centers to investigate the use of high-
ose therapy and stem cell transplantation in adult
LL patients [10,11,13,14,16,17,25,26]. Allogeneic
SCT is currently known as the best antileukemic
reatment for adult patients with non-Burkitt ALL by
ost authors, even if results on survival are impaired
y a high treatment-related mortality rate [10,13-
7,25]. Several previous studies have reported on the
ncreased toxicity after intensiﬁed conditioning regi-
ens in alloBMT [11,13,17,27]. The analyses of the 2
OELAMS studies conﬁrm the good antileukemic
ffects of alloBMT and also the potential toxicity of
he procedure. The difference between groups con-
ists only of an excess in the treatment-related mor-
ality for the GOELAL1 patients; the antileukemic
ffect, as illustrated by the DFS, is similar. The initial
haracteristics of the patients at transplantation
howed some heterogeneity, especially with a trend in
younger age for the LALPOF patients, and these
ifferences between the 2 cohorts, even if not statis-
igure 4. Event-free survival according to the protocol assignment.
t 48 months (4 years): LALPOF, 66%  11% (continuous line);
OELAL, 35%  11% (dotted line) (P  .02).
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Intensified Allogeneic BMT in ALL
Bically signiﬁcant, indicated some limitations in our
nterpretation of the data. This fact alone cannot ex-
lain the difference observed in the transplant-related
ortality after transplantation, and the difference of
ge in surviving patients is not signiﬁcant. The sup-
ortive care practices that improved over time had no
ffect on our results, because GOELAL1 is the more
ecent protocol and had the unexpected higher toxic-
ty rate. The clear-cut discrepancy in toxic death rates
etween protocols, translated in the respective EFS
nd global survival, have convinced us that we cannot
ntensify both pretransplantation chemotherapy and
he conditioning regimen.
Taking into account the cumulative experience of
hese results, and in an attempt to improve the prognosis
f these ALL patients and to reduce transplant-related
ortality, the GOELAMS prospectively evaluated, in a
urther trial (GOELAL02) [12], the therapeutic value of
arly HLA-matched sibling alloBMT with an intensi-
ed conditioning regimen after standard induction
herapy. Brieﬂy, 198 patients with a median age of 33
ears were included. The CR rate was 80% with
incristine, idarubicin, l-asparaginase, and random-
zed IV or oral steroids (not signiﬁcant). Allogeneic
MT was performed after 2 standard consolidation
ourses. The intensiﬁed conditioning regimen before
ransplantation included etoposide, CY, and TBI. In
his multicenter study, alloBMT was highly successful,
ith a 6-year DFS rate of 75% (95% conﬁdence
nterval, 61%-89%) for the 41 patients aged 50
ears with HLA-identical sibling donors. This is
igher than the 30% to 60% 5-year DFS reported in
revious multicenter studies [4,10,11,28]. These re-
ults are not related to a biased selection of good-risk
atients, because the distribution of poor-risk factors
as similar in the alloBMT group and the overall
opulation. This good outcome after alloBMT re-
ulted both from a high antileukemic effect of the
ntensiﬁed conditioning regimen [16] and from a low
ransplant-related mortality due to the early perfor-
ance, around day 90, of alloBMT, thus avoiding cu-
ulative toxicities before conditioning [4,7-9,16,17].
reatment-related mortality was decreased when allo-
MT was performed after low-intensity consolidation
ourses [13,29,30].
Our results suffer because we examined only a
imited number of patients, which is frequently en-
ountered for alloBMT in ALL, and from some het-
rogeneity, but both consecutive studies were con-
ucted prospectively in the same GOELAMS centers,
hich are used to working together and in the man-
gement of these patients. The differences observed
erit consideration. Chemotherapy dose intensity is
robably one of the mechanisms that plays an impor-
ant role in the improved outcome of ALL patients.
he overall survival advantage observed with al-oBMT when a low transplant-related mortality is
B & M Tbtained is in favor of a beneﬁt of the graft-versus-
eukemia effect. We must ﬁnd the best way to com-
ine these 2 strategies without adding their potential
oxicities. The intensive treatment could take place
uring the conditioning regimen of alloBMT or be-
ore the transplantation procedure, during the induc-
ion or the early consolidation phase, but we must be
autious when combining both approaches.
EFERENCES
1. Gokbuget N, Hoelzer D. Recent approaches in acute lympho-
blastic leukemia in adults. Rev Clin Exp Hematol. 2002;6:114-
141.
2. Hoelzer D, Gokbuget N. New approaches to acute lympho-
blastic leukemia in adults: where do we go? Semin Oncol. 2000;
27:540-559.
3. Hoelzer D, Gokbuget N, Ottmann O, et al. Acute lymphoblas-
tic leukemia. Hematology (Am Soc Hematol Educ Program). 2002:
162-192.
4. Ifrah N, Witz F, Jouet JP, et al. Intensive short-term therapy
with granulocyte-macrophage-colony stimulating factor sup-
port, similar to therapy for acute myeloblastic leukemia, does
not improve overall results for adults with acute lymphoblastic
leukemia. GOELAMS Group. Cancer. 1999;86:1496-1505.
5. Linker C, Damon L, Ries C, Navarro W. Intensiﬁed and
shortened cyclical chemotherapy for adult acute lymphoblastic
leukemia. J Clin Oncol. 2002;20:2464-2471.
6. Petersdorf S, Kopecky K, Head D, et al. Comparison of the
L10M consolidation regimen to an alternative regimen includ-
ing escalating methotrexate/L-asparaginase for adult acute lym-
phoblastic leukemia: a Southwest Oncology Group Study. Leu-
kemia. 2001;15:208-216.
7. Sotomayor EM, Piantadosi S, Miller CB, et al. Long-term
follow-up of intensive ara-C-based chemotherapy followed by
bone marrow transplantation for adult acute lymphoblastic leu-
kemia: impact of induction Ara-C dose and post-remission
therapy. Leuk Res. 2002;26:461-471.
8. Todeschini G. High-dose anthracycline induction in adult
acute lymphocytic leukemia. Hematol Oncol Clin North Am.
2001;15:9-20.
9. Yates J, Glidewell O, Wiernik P, et al. Cytosine arabinoside
with daunorubicin or adriamycin for therapy of acute myelo-
cytic leukemia: a CALGB study. Blood. 1982;60:454-462.
0. Attal M, Blaise D, Marit G, et al. Consolidation treatment of
adult acute lymphoblastic leukemia: a prospective, randomized
trial comparing allogeneic versus autologous bone marrow
transplantation and testing the impact of recombinant interleu-
kin-2 after autologous bone marrow transplantation. BGMT
Group. Blood. 1995;86:1619-1628.
1. Bassan R, Pogliani E, Casula P, et al. Risk-oriented postre-
mission strategies in adult acute lymphoblastic leukemia: pro-
spective conﬁrmation of anthracycline activity in standard-risk
class and role of hematopoietic stem cell transplants in high-
risk groups. Haematologica. 2001;2:117-126.
2. Hunault M, Harousseau JL, Delain M, et al. Better outcome of
adult acute lymphoblastic leukemia after early genoidentical
allogeneic bone marrow transplantation (BMT) than after late
high-dose therapy and autologous BMT: a GOELAMS trial.
Blood. 2004;104:3028-3037.
453
11
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
E. Deconinck et al.
43. Sebban C, Lepage E, Vernant JP, et al. Allogeneic bone mar-
row transplantation in adult acute lymphoblastic leukemia in
ﬁrst complete remission: a comparative study. French Group of
Therapy of Adult Acute Lymphoblastic Leukemia. J Clin Oncol.
1994;12:2580-2587.
4. Barrett AJ. Allogeneic bone marrow transplantation for acute
lymphoblastic leukaemia. Leukemia. 1992;6(suppl 2):139-143.
5. Cornelissen JJ, Carston M, Kollman C, et al. Unrelated marrow
transplantation for adult patients with poor-risk acute lympho-
blastic leukemia: strong graft-versus-leukemia effect and risk
factors determining outcome. Blood. 2001;97:1572-1577.
6. Petersen FB, Buckner CD, Appelbaum FR, et al. Etoposide,
cyclophosphamide and fractionated total body irradiation as a
preparative regimen for marrow transplantation in patients
with advanced hematological malignancies: a phase I study.
Bone Marrow Transplant. 1992;10:83-88.
7. Deconinck E, Cahn JY, Milpied N, et al. Allogeneic bone
marrow transplantation for high-risk acute lymphoblastic leu-
kemia in ﬁrst remission: long-term results for 42 patients con-
ditioned with an intensiﬁed regimen (TBI, high-dose Ara-C
and melphalan). Bone Marrow Transplant. 1997;20:731-735.
8. Hunault-Berger M, Milpied N, Bernard M, et al. Daunorubicin
continuous infusion induces more toxicity than bolus infusion
in acute lymphoblastic leukemia induction regimen: a random-
ized study. Leukemia. 2001;15:898-902.
9. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the
classiﬁcation of the acute leukaemias. French-American-British
(FAB) co-operative group. Br J Haematol. 1976;33:451-458.
0. Bene MC, Castoldi G, Knapp W, et al. Proposals for the
immunological classiﬁcation of acute leukemias. European
Group for the Immunological Characterization of Leukemias
(EGIL). Leukemia. 1995;9:1783-1786.
1. Cytogenetic abnormalities in adult acute lymphoblastic leuke-
mia. correlations with hematologic ﬁndings outcome. A Col-
54laborative Study of the Group Francais de Cytogenetique
Hematologique. Blood. 1996;87:3135-3142.
2. An International System for Human Cytogenetic Nomencla-
ture (1985) ISCN 1985. Report of the Standing Committee on
Human Cytogenetic Nomenclature. Birth Defects Orig Artic Ser.
1985;21:1-117.
3. Kaplan E, Meier P. Nonparametric estimation from incomplete
observations. J Am Stat Assoc. 1958;53:457-481.
4. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statis-
tics, 2000. CA Cancer J Clin. 2000;50:7-33.
5. Annino L, Vegna ML, Camera A, et al. Treatment of adult
acute lymphoblastic leukemia (ALL): long-term follow-up of
the GIMEMA ALL 0288 randomized study. Blood. 2002;99:
863-871.
6. Oh H, Gale R, Zhang M, et al. Chemotherapy vs HLA-iden-
tical sibling bone marrow transplants for adults with acute
lymphoblastic leukemia in ﬁrst remission. Bone Marrow Trans-
plant. 1998;22:253-257.
7. Esperou H, Boiron JM, Cayuela JM, et al. A potential graft-
versus-leukemia effect after allogeneic hematopoietic stem cell
transplantation for patients with Philadelphia chromosome-
positive acute lymphoblastic leukemia: results from the French
Bone Marrow Transplantation Society. Bone Marrow Trans-
plant. 2003;31:909-918.
8. Horowitz MM, Messerer D, Hoelzer D, et al. Chemotherapy
compared with bone marrow transplantation for adults with
acute lymphoblastic leukemia in ﬁrst remission. Ann Intern
Med. 1991;115:13-18.
9. Blaise D, Gaspard MH, Stoppa AM, et al. Allogeneic or autol-
ogous bone marrow transplantation for acute lymphoblastic
leukemia in ﬁrst complete remission. Bone Marrow Transplant.
1990;5:7-12.
0. Vey N, Blaise D, Stoppa AM, et al. Bone marrow transplantation
in 63 adult patients with acute lymphoblastic leukemia in ﬁrst
complete remission. Bone Marrow Transplant. 1994;14:383-388.
